Immunocore Holdings plc
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
(Unaudited) (In thousands, except share and per share data)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $452,675 | $467,709 |
| Marketable securities | 392,221 | 396,444 |
| Accounts receivable, net | 81,068 | 73,977 |
| Prepaid expenses and other current assets | 69,590 | 51,870 |
| Inventory, net | 8,253 | 6,742 |
| Total current assets | 1,003,807 | 996,742 |
| Property and equipment, net | 12,128 | 11,462 |
| Operating lease right of use assets, net | 37,546 | 38,783 |
| Other non-current assets | 18,614 | 20,282 |
| Total assets | $1,072,095 | $1,067,269 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $30,157 | $24,364 |
| Accrued expenses and other current liabilities | 207,388 | 219,744 |
| Deferred revenue, current | 572 | 583 |
| Operating lease liabilities, current | 1,996 | 2,006 |
| Total current liabilities | 240,113 | 246,697 |
| Deferred revenue, non-current | 4,622 | 4,858 |
| Operating lease liabilities, non-current | 40,027 | 41,556 |
| Interest-bearing loans and borrowings | 393,660 | 393,125 |
| Total liabilities | 678,422 | 686,236 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity | ||
| Ordinary shares (voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and shares as of March 31, 2026 and December 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 137 | 136 |
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025. | 1 | 1 |
| Additional paid-in capital | 1,247,212 | 1,240,255 |
| Accumulated deficit | (818,304) | (831,275) |
| Accumulated other comprehensive loss | (35,373) | (28,084) |
| Total shareholders' equity | 393,673 | 381,033 |
| Total liabilities and shareholders' equity | $1,072,095 | $1,067,269 |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(Unaudited) (In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| Revenue from sale of therapies, net | $106,677 | $93,881 |
| Total revenue | 106,677 | 93,881 |
| Cost and operating expenses: | ||
| Cost of revenue from sale of therapies | (434) | (831) |
| Research and development expense | (61,113) | (56,468) |
| Selling, general and administrative expense | (37,850) | (40,198) |
| Income (Loss) from operations | 7,280 | (3,616) |
| Other income (expense): | ||
| Interest income | 3,418 | 4,176 |
| Interest expense | (3,051) | (3,025) |
| Foreign currency gains | 3,849 | 3,080 |
| Other income, net | 1,776 | 5,469 |
| Net income before income taxes | 13,272 | 6,084 |
| Income tax expense | (301) | (1,061) |
| Net income | $12,971 | $5,023 |
| Other comprehensive income (loss): | ||
| Exchange differences on translation of foreign operations | (7,289) | 673 |
| Total comprehensive income | $5,682 | $5,696 |
| Basic net income per share | $0.26 | $0.10 |
| Basic weighted-average number of shares outstanding | 50,754,763 | 50,086,684 |
| Diluted net income per share | $0.25 | $0.10 |
| Diluted weighted-average number of shares outstanding | 52,934,787 | 51,949,798 |
Condensed Consolidated Statements of Shareholders’ Equity
(Unaudited) (In thousands, except share data)
| Ordinary Shares · Deferred Shares · Additional Paid-in Capital · Accumulateddeficit · Accumulated other comprehensive (loss) income · Total Shareholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||
| As of December 31, 2025 | 50,689,271 | $136 | 5,793,501 | $1 | $1,240,255 | $(831,275) | $(28,084) | $381,033 |
| Net income | — | — | — | — | — | 12,971 | — | 12,971 |
| Other comprehensive loss | — | — | — | — | — | — | (7,289) | (7,289) |
| Equity plan options exercised and units assigned | 142,657 | 1 | — | — | 655 | — | — | 656 |
| Share-based compensation expense | — | — | — | — | 6,302 | — | — | 6,302 |
| As of March 31, 2026 | 50,831,928 | $137 | 5,793,501 | $1 | $1,247,212 | $(818,304) | $(35,373) | $393,673 |
| Ordinary Shares · Deferred Shares · Additional Paid-in Capital · Accumulateddeficit · Accumulated other comprehensive (loss) income · Total Shareholders' Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||||||
| As of December 31, 2024 | 50,064,860 | $135 | 5,793,501 | $1 | $1,190,104 | $(795,761) | $(33,763) | $360,716 | |||
| Net income | — | — | — | — | — | 5,023 | — | 5,023 | |||
| Other comprehensive income | — | — | — | — | — | — | 673 | 673 | |||
| Exercise of share options | 119,749 | — | — | — | 2,551 | — | — | 2,551 | |||
| Share-based compensation expense | — | — | — | — | 9,516 | — | — | 9,516 | |||
| As of March 31, 2025 | 50,184,609 | $135 | 5,793,501 | $1 | $1,202,171 | $(790,738) | $(33,090) | $378,479 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.